Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition)

Liver Cancer

Volumn 7, Issue 3, 2018, Pages 235-260

  Zhou, Jian ^a   Sun, Hui Chuan ^a   Wang, Zheng ^a   Cong, Wen Ming ^b   Wang, Jian Hua ^a   Zeng, Meng Su ^a   Yang, Jia Mei ^b   Bie, Ping ^c   Liu, Lian Xin ^d   Wen, Tian Fu ^e   Han, Guo Hong ^f   Wang, Mao Qiang ^g   Liu, Rui Bao ^d   Lu, Li Gong ^h   Ren, Zheng Gang ^a   Chen, Min Shan ⁱ   Zeng, Zhao Chong ^a   Liang, Ping ^g   Liang, Chang Hong ^h   Chen, Min ^j   Yan, Fu Hua ^k   Wang, Wen Ping ^a   Ji, Yuan ^a   Cheng, Wen Wu ^a   Dai, Chao Liu ^l   Jia, Wei Dong ^m   Li, Ya Ming ^l   Li, Ye Xiong ⁿ   Liang, Jun ^o   Liu, Tian Shu ^a   Lv, Guo Yue ^p   Mao, Yi Lei ^q   Ren, Wei Xin ^r   Shi, Hong Cheng ^a   Wang, Wen Tao ^e   Wang, Xiao Ying ^a   Xing, Bao Cai ^s   Xu, Jian Ming ^t   Yang, Jian Yong ^u   Yang, Ye Fa ^b   Ye, Sheng Long ^a   Yin, Zheng Yu ^v   Zhang, Bo Heng ^a   Zhang, Shui Jun ^w   Zhou, Wei Ping ^b   Zhu, Ji Ye ^x   Liu, Rong ^a   Shi, Ying Hong ^a   Xiao, Yong Sheng ^a   Dai, Zhi ^a   Teng, Gao Jun ^y   Cai, Jian Qiang ^z   Wang, Wei Lin ^aa   Dong, Jia Hong ^ab   Li, Qiang ^ac   Shen, Feng ^b   Qin, Shu Kui ^ad   Fan, Jia ^a   more..

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e SICHUAN UNIVERSITY   (China)

^f FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^g CHINESE PLA GENERAL HOSPITAL   (China)

^h GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

ⁱ SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^j Edit Department of Chinese Journal of Digestive Surgery   (China)

^k SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^l CHINA MEDICAL UNIVERSITY   (China)

^m ANHUI MEDICAL UNIVERSITY   (China)

ⁿ PEKING UNION MEDICAL COLLEGE   (China)

^o PEKING UNIVERSITY INTERNATIONAL HOSPITAL   (China)

^p JILIN UNIVERSITY   (China)

^q PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^r XINJIANG MEDICAL UNIVERSITY   (China)

^s PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^t BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^u SUN YAT SEN UNIVERSITY   (China)

^v XIAMEN UNIVERSITY   (China)

^w THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^x PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^y SOUTHEAST UNIVERSITY   (China)

^z CANCER HOSPITAL   (China)

^aa ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^ab TSINGHUA UNIVERSITY   (China)

^ac TIANJIN MEDICAL UNIVERSITY   (China)

^ad Nanjing Bayi Hospital   (China)

more..

Author keywords

Cancer; Carcinoma; China; Diagnosis; Liver; Treatment

Indexed keywords

ACETIC ACID C 11; ALPHA FETOPROTEIN; ALPHA INTERFERON; ARSENIC TRIOXIDE; CALCINEURIN INHIBITOR; CHOLINE C 11; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOXETIC ACID; HERBACEOUS AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOMYCIN; NUCLEOSIDE ANALOG; OXALIPLATIN; SORAFENIB;

BRACHYTHERAPY; CANCER IMMUNOTHERAPY; CANCER SCREENING; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGITAL SUBTRACTION ANGIOGRAPHY; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HEPATITIS B; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CANCER; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER FUNCTION RESERVE; LIVER RESECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER WEIGHT; MICROWAVE THERMOTHERAPY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS ETHANOL INJECTION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RASH; REMNANT LIVER VOLUME; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; SURGICAL TECHNIQUE; TUMOR ABLATION; TUMOR RECURRENCE;

EID: 85048589014     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000488035     Document Type: Review

References (124)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J: Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115-132.
3. Zhang BH, Yang BH, Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
4. Salvatore V, Gianstefani A, Negrini G, Allegretti G, Galassi M, Piscaglia F: Imaging diagnosis of hepatocellular carcinoma: Recent advances of contrast-enhanced ultrasonography with SonoVue® . Liver Cancer 2016; 5: 55-66.
5. Zeng MS, Ye HY, Guo L, Peng WJ, Lu JP, Teng GJ, Huan Y, Li P, Xu JR, Liang CH, Breuer J: Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients: A multicenter, open-label, phase III study. Hepatobiliary Pancreat Dis Int 2013; 12: 607-616.
6. Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, Kim YH, Han JK, Choi BI: Hepatocellular carcinoma: Diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015; 275: 97-109.
7. Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y, Kamura T, Gabata T, Murakami T, Ito K, Hirohashi S, Nishie A, Saito Y, Onaya H, Kuwatsuru R, Morimoto A, Ueda K, Kurauchi M, Breuer J: Detection and characterization of focal liver lesions: A Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010; 45: 133-141.
8. Yoo SH, Choi JY, Jang JW, Bae SH, Yoon SK, Kim DG, Yoo YK, Rha SE, Lee YJ, Jung ES: Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma. Ann Surg Oncol 2013; 20: 2893-2900.
9. Chen CZ, Rao SX, Ding Y, Zhang SJ, Li F, Gao Q, Zeng MS: Hepatocellular carcinoma 20 mm or smaller in cirrhosis patients: Early magnetic resonance enhancement by gadoxetic acid compared with gadopentetate dimeglumine. Hepatol Int 2014; 8: 104-111.
10. Joo I, Lee JM: Recent advances in the imaging diagnosis of hepatocellular carcinoma: Value of gadoxetic acidenhanced MRI. Liver Cancer 2016; 5: 67-87.
11. Chen BB, Murakami T, Shih TT, Sakamoto M, Matsui O, Choi BI, Kim MJ, Lee JM, Yang RJ, Zeng MS, Chen RC, Liang JD: Novel imaging diagnosis for hepatocellular carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2015; 4: 215-227.
12. Merkle EM, Zech CJ, Bartolozzi C, Bashir MR, Ba-Ssalamah A, Huppertz A, Lee JM, Ricke J, Sakamoto M, Sirlin CB, Ye SL, Zeng M: Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 2016; 26: 674-682.
13. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ; European Association of Nuclear Medicine: FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur J Nucl Med Mol Imaging 2015; 42: 328-354.
14. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
15. Ferda J, Ferdova E, Baxa J, Kreuzberg B, Daum O, Treska V, Skalicky T: The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography. Anticancer Res 2015; 35: 2241-2246.
16. Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim do Y, Kim SU, Moon DH, Lee JD, Yun M: Prognostic significance of 18F-FDG uptake in hepatocellular carcinoma treated with transarterial chemoembolization or concurrent chemoradiotherapy: A multicenter retrospective cohort study. J Nucl Med 2016; 57: 509-516.
17. Hyun SH, Eo JS, Lee JW, Choi JY, Lee KH, Na SJ, Hong IK, Oh JK, Chung YA, Song BI, Kim TS, Kim KS, Moon DH, Yun M: Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: A multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging, Epub ahead of print.
18. Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH: A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008; 49: 1912-1921.
19. Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH: 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Radiol 2012; 81: 2417-2422.
20. Wahl RL, Jacene H, Kasamon Y, Lodge MA: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50(suppl 1): 122S-150S.
21. Chalian H, Tore HG, Horowitz JM, Salem R, Miller FH, Yaghmai V: Radiologic assessment of response to therapy: Comparison of RECIST Versions 1.1 and 1.0. Radiographics 2011; 31: 2093-2105.
22. Zhang Y, Shi H, Li B, Cai L, Gu Y, Xiu Y: The added value of SPECT/spiral CT in patients with equivocal bony metastasis from hepatocellular carcinoma. Nuklearmedizin 2015; 54: 255-261.
23. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Bru C, Bruix J: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104.
24. Nara S, Shimada K, Sakamoto Y, Esaki M, Kishi Y, Kosuge T, Ojima H: Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: Evidence from 570 hepatectomies. Surgery 2012; 151: 526-536.
25. Bass BP, Engel KB, Greytak SR, Moore HM: A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: How well do you know your FFPE specimen? Arch Pathol Lab Med 2014; 138: 1520-1530.
26. Westra WH, Hruban RH, Phelps TH, Isacson C: Surgical Pathology Dissection: An Illustrated Guide. New York, Springer, 2003.
27. Lu XY, Xi T, Lau WY, Dong H, Zhu Z, Shen F, Wu MC, Cong WM: Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior. Ann Surg Oncol 2011; 18: 2210-2217.
28. Cong WM, Bu H, Chen J, et al: Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol 2016; 22: 9279-9287.
29. Scheuer PJ: Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-374.
30. WHO: Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva, WHO, 2015.
31. Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK: A systematic review of microvascular invasion in hepatocellular carcinoma: Diagnostic and prognostic variability. Ann Surg Oncol 2013; 20: 325-339.
32. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I, Kanematsu T: Predictor for histological microvascular invasion of hepatocellular carcinoma: A lesson from 229 consecutive cases of curative liver resection. World J Surg 2010; 34: 1034-1038.
33. Fujita N, Aishima S, Iguchi T, Mano Y, Taketomi A, Shirabe K, Honda H, Tsuneyoshi M, Oda Y: Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma. Hum Pathol 2011; 42: 1531-1538.
34. Iguchi T, Shirabe K, Aishima S, Wang H, Fujita N, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T, Oda Y, Maehara Y: New pathologic stratification of microvascular invasion in hepatocellular carcinoma: Predicting prognosis after living-donor liver transplantation. Transplantation 2015; 99: 1236-1242.
35. Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, Takayama T, Makuuchi M: One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138: 1198-1206; discussion 1206.
36. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T: Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997; 26: 1176-1181.
37. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, Bru C, Rodes J: Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-1022.
38. Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, Festi D, Pinna AD: Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012; 256: 706-712; discussion 712-703.
39. Mise Y, Sakamoto Y, Ishizawa T, Kaneko J, Aoki T, Hasegawa K, Sugawara Y, Kokudo N: A worldwide survey of the current daily practice in liver surgery. Liver Cancer 2013; 2: 55-66.
40. Liu PH, Hsu CY, Hsia CY, Lee YH, Huang YH, Chiou YY, Lin HC, Huo TI: Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma
41. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J: A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57: 794-802.
42. Xu Q, Kobayashi S, Ye X, Meng X: Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: A meta-analysis of 16,103 patients. Sci Rep 2014; 4: 7252.
43. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328.
44. Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC, Zhou WP: Partial hepatectomy versus transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: A RCT. J Hepatol 2014; 61: 82-88.
45. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E, Makuuchi M: A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: Is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Ann Surg 2013; 257: 929-937.
46. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M: Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916.
47. Jiang HT, Cao JY: Impact of laparoscopic versus open hepatectomy on perioperative clinical outcomes of patients with primary hepatic carcinoma. Chin Med Sci J 2015; 30: 80-83.
48. Tang ZY, Uy YQ, Zhou XD, Ma ZC, Lu JZ, Lin ZY, Liu KD, Ye SL, Yang BH, Wang HW, et al: Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: Evaluation with analysis of 72 patients. World J Surg 1995; 19: 784-789.
49. Tang ZY, Yu YQ, Zhou XD, Ma ZC, Yang BH, Lin ZY, Lu JZ, Liu KD, Fan Z, Zeng ZC: Treatment of unresectable primary liver cancer: With reference to cytoreduction and sequential resection. World J Surg 1995; 19: 47-52.
50. Wakabayashi H, Okada S, Maeba T, Maeta H: Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured livers: A preliminary report. Surg Today 1997; 27: 403-410.
51. Aoki T, Kubota K: Preoperative portal vein embolization for hepatocellular carcinoma: Consensus and controversy. World J Hepatol 2016; 8: 439-445.
52. Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V: Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006; 93: 1091-1098.
53. D'Haese JG, Neumann J, Weniger M, Pratschke S, Bjornsson B, Ardiles V, Chapman W, Hernandez-Alejandro R, Soubrane O, Robles-Campos R, Stojanovic M, Dalla Valle R, Chan AC, Coenen M, Guba M, Werner J, Schadde E, Angele MK: Should ALPPS be used for liver resection in intermediate-stage HCC? Ann Surg Oncol 2016; 23: 1335-1343.
54. Hong de F, Zhang YB, Peng SY, Huang DS: Percutaneous microwave ablation liver partition and portal vein embolization for rapid liver regeneration: A minimally invasive first step of ALPPS for hepatocellular carcinoma. Ann Surg 2016; 264:e1-e2.
55. Liu CL, Fan ST, Lo CM, Tung-Ping Poon R, Wong J: Anterior approach for major right hepatic resection for large hepatocellular carcinoma. Ann Surg 2000; 232: 25-31.
56. Zhang ZM, Lai EC, Zhang C, Yu HW, Liu Z, Wan BJ, Liu LM, Tian ZH, Deng H, Sun QH, Chen XP: The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg 2015; 20: 8-16.
57. Fu SY, Lau WY, Li AJ, Yang Y, Pan ZY, Sun YM, Lai EC, Zhou WP, Wu MC: Liver resection under total vascular exclusion with or without preceding Pringle manoeuvre. Br J Surg 2010; 97: 50-55.
58. Satoh S, Ikai I, Honda G, Okabe H, Takeyama O, Yamamoto Y, Yamamoto N, Iimuro Y, Shimahara Y, Yamaoka Y: Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi. Surgery 2000; 128: 779-783.
59. Shi HY, Wang SN, Wang SC, Chuang SC, Chen CM, Lee KT: Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: A nationwide Taiwan database analysis of long-term outcome predictors. J Surg Oncol 2014; 109: 487-493.
60. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY, Wu MC: A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 2009; 249: 195-202.
61. Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L: Treatment stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: An observational study. Liver Cancer 2017; 6: 313-324.
62. Ren ZG, Lin ZY, Xia JL, Ye SL, Ma ZC, Ye QH, Qin LX, Wu ZQ, Fan J, Tang ZY: Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: A retrospective control study. World J Gastroenterol 2004; 10: 2791-2794.
63. Fan J, Zhou J, Wu ZQ, Qiu SJ, Wang XY, Shi YH, Tang ZY: Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2005; 11: 1215-1219.
64. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM; HCC Italian Task Force: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554.
65. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842.
66. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: A randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465.
67. Nishiguchi S, Tamori A, Kubo S: Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 71-75.
68. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447.
69. Fan J, Yang GS, Fu ZR, Peng ZH, Xia Q, Peng CH, Qian JM, Zhou J, Xu Y, Qiu SJ, Zhong L, Zhou GW, Zhang JJ: Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: A multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 2009; 135: 1403-1412.
70. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM: Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-1732.
71. Li J, Yan LN, Yang J, Chen ZY, Li B, Zeng Y, Wen TF, Zhao JC, Wang WT, Yang JY, Xu MQ, Ma YK: Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. World J Gastroenterol 2009; 15: 4170-4176.
72. Rodriguez-Peralvarez M, Tsochatzis E, Naveas MC, Pieri G, Garcia-Caparros C, O'Beirne J, Poyato-Gonzalez A, Ferrin-Sanchez G, Montero-Alvarez JL, Patch D, Thorburn D, Briceno J, De la Mata M, Burroughs AK: Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199.
73. Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He X: Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis. Liver Transplant 2012; 18: 62-69.
74. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J: Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40: 3548-3553.
75. Hasegawa K, Aoki T, Ishizawa T, Kaneko J, Sakamoto Y, Sugawara Y, Kokudo N: Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma. Ann Surg Oncol 2014; 21(suppl 3):S348-S355.
76. Li L, Zhang J, Liu X, Li X, Jiao B, Kang T: Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta-analysis. J Gastroenterol Hepatol 2012; 27: 51-58.
77. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y: A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912.
78. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY: Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial. J Clin Oncol 2013; 31: 426-432.
79. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K: Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116: 5452-5460.
80. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, Van Steenbergen W, Buffet C, Rougier P, Adler M, Pignon JP, Roche A: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29: 129-134.
81. Di Vece F, Tombesi P, Ermili F, Maraldi C, Sartori S: Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects: A prospective pilot study. Cardiovasc Intervent Radiol 2014; 37: 723-729.
82. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF: Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 2016; 64: 106-116.
83. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
84. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J; Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359: 1734-1739.
85. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M: Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54.
86. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442.
87. Coordination Group IMG, Society of Radiology, Chinese Medical Association: Expert consensus for standard operating procedures for transcatheter arterial chemoembolization for primary hepatocellular carcinoma. Chin J Radiol 2011; 45: 908-912.
88. Yang M, Fang Z, Yan Z, Luo J, Liu L, Zhang W, Wu L, Ma J, Yang Q, Liu Q: Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: A two-arm, randomised clinical trial. J Cancer Res Clin Oncol 2014; 140: 211-219.
89. Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK: Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-1250.
90. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Study Investigators: Prospective randomized study of doxorubicineluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
91. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F; Precision Italia Study Group: Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264.
92. Lee YK, Jung KS, Kim DY, Choi JY, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim GM, Kim MD, Park SI, Won JY, Lee DY: Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. J Gastroenterol Hepatol 2017; 32: 487-496.
93. Geschwind JF, Gholam PM, Goldenberg A, Mantry P, Martin RC, Piperdi B, Zigmont E, Imperial J, Babajanyan S, Foreman PK, Cohn A: Use of transarterial chemoembolization (TACE) and sorafenib in patients with unresectable hepatocellular carcinoma: US regional analysis of the GIDEON Registry. Liver Cancer 2016; 5: 37-46.
94. Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M: Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer 2015; 4: 253-262.
95. Zeng ZC, Tang ZY, Fan J, Zhou J, Qin LX, Ye SL, Sun HC, Wang BL, Yu Y, Wang JH, Guo W: A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 2004; 10: 307-316.
96. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, Zhang RM: Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Radiother Oncol 2009; 92: 184-194.
97. Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, Sun HC, Wang BL, Zhang JY, Jiang GL, Wang YQ: A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005; 61: 432-443.
98. Yoon HI, Seong J: Optimal selection of radiotherapy as part of a multimodal approach for hepatocellular carcinoma. Liver Cancer 2016; 5: 139-151.
99. Zeng ZC, Tang ZY, Fan J, Qin LX, Ye SL, Zhou J, Sun HC, Wang BL, Wang JH: Consideration of role of radiotherapy for lymph node metastases in patients with HCC: Retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys 2005; 63: 1067-1076.
100. Zhou LY, Zeng ZC, Fan J, Chen B, Rao SX, He J, Yang P, Hou JZ, Wu ZF, Zhang JY, Hu Y: Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: Clinical features and prognostic factors. BMC Cancer 2014; 14: 878-887.
101. He J, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, Wang JH, Sun J, Chen B, Yang P, Pan BS: Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 2009; 115: 2710-2720.
102. Wang WH, Wang Z, Wu JX, Zhang T, Rong WQ, Wang LM, Jin J, Wang SL, Song YW, Liu YP, Ren H, Fang H, Wang WQ, Liu XF, Yu ZH, Li YX: Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels. Liver Int 2015; 35: 2603-2610.
103. Wang MH, Ji Y, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, Bi AH, Tan YS: Impact factors for microinvasion in patients with hepatocellular carcinoma: Possible application to the definition of clinical tumor volume. Int J Radiat Oncol Biol Phys 2010; 76: 467-476.
104. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK: Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002; 53: 810-821.
105. Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL: Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006; 65: 426-434.
106. Chon YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Shin SK, Kim DY: Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: Endoscopic findings and risk factors. Int J Radiat Oncol Biol Phys 2011; 81: 1343-1351.
107. Hou JZ, Zeng ZC, Wang BL, Yang P, Zhang JY, Mo HF: High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT. Jpn J Clin Oncol 2016; 46: 357-362.
108. Hu Y, Zhou YK, Chen YX, Shi SM, Zeng ZC: 4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy. Med Phys 2016; 43: 4335.
109. Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, Liang PC, Santos-Ocampo RS, Lo RH, Lim KB, Tai DW, Ng DC, Irani FG, Gogna A, Chow PK: Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol 2016; 12: 1193-1204.
110. Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL: Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 2015; 4: 16-25.
111. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z, Chen ZN: A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45: 269-276.
112. Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, Gosselin M: Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: Intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35: 1782-1787.
113. Cucchetti A, Piscaglia F, Pinna AD, Djulbegovic B, Mazzotti F, Bolondi L: Efficacy and safety of systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of phase III trials. Liver Cancer 2017; 6: 337-348.
114. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
115. Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A: Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: A prospective feasibility analysis. Ann Oncol 2013; 24: 406-411.
116. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y: Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31: 3501-3508.
117. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH: Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148: 1383-1391 e1386.
118. Kudo M: Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver Cancer 2016; 6: 1-12.
119. Xu L, Wang J, Kim Y, Shuang ZY, Zhang YJ, Lao XM, Li YQ, Chen MS, Pawlik TM, Xia JC, Li SP, Lau WY: A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology 2016; 5:e1083671.
120. Zeeneldin AA, Eid SM, Darweesh AD, Moneer MM, Saadeldin M: Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma: A retrospective matched-cohort study. J Egypt Natl Cancer Inst 2014; 26: 1-7.
121. Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, Takahashi M, Arai Y; Japan Interventional Radiology in Oncology Study Group JIVROSG: Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci 2013; 118: 16-22.
122. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
123. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G: Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: A two-stage longitudinal clinical study. J Clin Oncol 2013; 31: 3647-3655.
124. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP, Wu MC: Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: A randomized controlled trial. Ann Surg 2015; 261: 56-66.